Pharmacology of thromboxane synthetase inhibitors.
Several selective and potent thromboxane synthetase inhibitors have now been described. In this paper I shall summarize their effects on platelet aggregation, endotoxin- and thrombin-induced pulmonary hypertension, the Forssman reaction-induced thrombocytopenia, and the rat tail vein bleeding time. Although any clinical utility of thromboxane synthetase inhibition remains to be demonstrated, it may be useful in conditions where vasoconstriction or vasospasm are involved, particularly where platelet activation is a contributing factor.
D000818:Animals; D001760:Bleeding Time; D001792:Blood Platelets / Q000378:metabolism; D006976:Hypertension, Pulmonary / Q000139:chemically induced / Q000503:physiopathology; D007093:Imidazoles / Q000494:pharmacology; D010974:Platelet Aggregation / Q000187:drug effects; D011449:Prostaglandin Endoperoxides / Q000378:metabolism; D013329:Structure-Activity Relationship; D013921:Thrombocytopenia / Q000139:chemically induced / Q000503:physiopathology; D013928:Thromboxane A2 / Q000096:biosynthesis; D013930:Thromboxane-A Synthase / Q000037:antagonists & inhibitors*; D014661:Vasoconstriction / Q000187:drug effects
D007093:Imidazoles; D011449:Prostaglandin Endoperoxides; D013928:Thromboxane A2; D013930:Thromboxane-A Synthase